Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) - Equities research analysts at Leerink Partnrs decreased their Q3 2025 EPS estimates for Oruka Therapeutics in a research note issued on Tuesday, August 12th. Leerink Partnrs analyst D. Risinger now anticipates that the company will earn ($0.60) per share for the quarter, down from their prior forecast of ($0.33). The consensus estimate for Oruka Therapeutics' current full-year earnings is ($3.41) per share. Leerink Partnrs also issued estimates for Oruka Therapeutics' Q4 2025 earnings at ($0.59) EPS, FY2025 earnings at ($2.02) EPS, FY2026 earnings at ($2.26) EPS, FY2027 earnings at ($1.76) EPS, FY2028 earnings at ($1.93) EPS and FY2029 earnings at ($1.59) EPS.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.02.
Several other brokerages have also recently issued reports on ORKA. HC Wainwright reissued a "buy" rating and set a $45.00 price target on shares of Oruka Therapeutics in a research report on Wednesday, July 23rd. BTIG Research began coverage on shares of Oruka Therapeutics in a research report on Thursday, May 22nd. They set a "buy" rating on the stock. Wedbush reissued an "outperform" rating and set a $40.00 price target on shares of Oruka Therapeutics in a research report on Tuesday. Finally, Wall Street Zen cut shares of Oruka Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday. One analyst has rated the stock with a sell rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Oruka Therapeutics presently has an average rating of "Buy" and a consensus target price of $40.38.
Read Our Latest Analysis on ORKA
Oruka Therapeutics Stock Performance
Shares of ORKA traded up $0.37 during mid-day trading on Thursday, hitting $15.37. 155,920 shares of the company's stock were exchanged, compared to its average volume of 147,320. The company has a market cap of $575.61 million, a price-to-earnings ratio of -5.47 and a beta of -0.35. Oruka Therapeutics has a fifty-two week low of $5.49 and a fifty-two week high of $52.32. The stock's 50-day moving average is $13.35 and its 200-day moving average is $11.53.
Institutional Trading of Oruka Therapeutics
A number of large investors have recently made changes to their positions in the company. JPMorgan Chase & Co. acquired a new stake in Oruka Therapeutics during the fourth quarter worth approximately $54,000. Geode Capital Management LLC raised its holdings in Oruka Therapeutics by 2,348.6% during the fourth quarter. Geode Capital Management LLC now owns 342,418 shares of the company's stock worth $6,643,000 after purchasing an additional 328,434 shares in the last quarter. Barclays PLC acquired a new stake in Oruka Therapeutics during the fourth quarter worth approximately $1,446,000. SR One Capital Management LP raised its holdings in Oruka Therapeutics by 14.7% during the fourth quarter. SR One Capital Management LP now owns 430,330 shares of the company's stock worth $8,344,000 after purchasing an additional 55,000 shares in the last quarter. Finally, B Group Inc. acquired a new stake in Oruka Therapeutics during the fourth quarter worth approximately $388,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.
About Oruka Therapeutics
(
Get Free Report)
Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
See Also
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access